China Said to Push Qualcomm to Lower Patent Fees for Phonemakers
China wants Qualcomm Inc. (QCOM) to accept lower royalty payments for technology used by domestic smartphone manufacturers, people familiar with the matter said, in a proposal that would hurt the chipmaker’s main source of profit.
A joint EPO-UNEP study: Patents and climate change mitigation technologies in Latin America and the Caribbean
This joint study by the EPO and the United Nations Environment Programme (UNEP) finds that Latin America and the Caribbean has considerable untapped renewable energy potential, which could be harnessed to serve the region’s rapidly growing energy needs. It concludes that the patent system has an important but largely under-exploited role to play in fostering climate-friendly innovation in the region, and also technology transfer to and from the region
Read More
FTC Staff Issues FY 2013 Report on Branded Drug Firms’ Patent Settlements with Generic Competitors
In Fiscal Year 2013, companies filed a total of 145 final patent dispute settlements, of which 29 created potential “pay-for-delay” agreements between branded and generic drug companies, according to a new Federal Trade Commission staff report. Although the number of potential pay-for-delay settlements is down from FY 2012, it is similar to FY 2010 and 2011.
CAFC Delivers Another Decision on Patentability of Myriad Patents
In Univ. of Utah Res. Foundation et al. v. Ambry Genetics Corp., No. 2014-1361 (Fed. Cir. Dec. 17, 2014), the Federal Circuit once again has weighed in on the patent eligibility of Myriad Genetics, Inc.’s patents related to BRCA1 and BRCA2 genes. In this case, a panel of three judges of the Federal Circuit considered claims of patents that were not previously before this court and were also not considered by the Supreme Court in Molecular Pathology v. Myriad, 133 S. Ct. 2107 (2013) (“Myriad”).
